Hepatitis C

Sharp Increase in Maternal HCV Infection in US

Sharp Increase in Maternal HCV Infection in US

Hepatitis C virus infections among pregnant women have nearly doubled between 2009 and 2014 in the United States according to the CDC.

HCV Infection Doubled in Reproductive-aged Women From 2006 to 2014

HCV Infection Doubled in Reproductive-aged Women From 2006 to 2014

Researchers found that there was a doubling in the number of reproductive-aged women with acute and past or present HCV infection in the National Notifiable Disease Surveillance System.

CDC: Rise in HCV Infections Tripled in Last 5 Years

CDC: Rise in HCV Infections Tripled in Last 5 Years

The CDC reports that new hepatitis C virus infections in the US have nearly tripled over 5 years.

Congressional Acts Pose Threat to National ID Health Initiatives

Congressional Acts Pose Threat to National ID Health Initiatives

By

Passage of the 2017 budget, along with congressional approval of the AHCA, leaves large holes in the funding of the proposed national approach to infectious disease control.

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

By

An investigational direct-acting antiviral treatment combination improves patient-reported outcomes in addition to sustained virologic response in patients with HCV, especially patients with cirrhosis.

Phase 3 Study Finds Pan-Genotypic HCV Regimen Highly Efficacious

Phase 3 Study Finds Pan-Genotypic HCV Regimen Highly Efficacious

By

Findings from the EXPEDITION-1 study, a phase 3 trial, evaluated the efficacy and safety of glecaprevir/pibrentasvir for the treatment of chronic HCV infection in patients with genotype 1, 2, 4, 5, or 6 and compensated cirrhosis.

Investigational Ledipasvir/Sofosbuvir Dose Safe in Children With HCV

Investigational Ledipasvir/Sofosbuvir Dose Safe in Children With HCV

By

Investigational dosage of once-daily ledipasvir/sofosbuvir was safe and highly efficacious in children age 6 to 11 with chronic HCV infection.

Clinical Practice Update on Managing Patients Cured of HCV Infection

Clinical Practice Update on Managing Patients Cured of HCV Infection

By

Patients with chronic HCV infection who have achieved a sustained virologic response with treatment are considered cured, but they may still be at risk for complications such as hepatocellular carcinoma. The American Gastroenterological Association Institute addresses these issues in its clinical practice update on managing patients cured of HCV infection.

Statins Reduce Risk of Cirrhosis Decompensation in HBV, HCV

Statins Reduce Risk of Cirrhosis Decompensation in HBV, HCV

By

Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and, to a lesser extent, in patients with alcohol-induced cirrhosis. Mortality rates were also reduced in statin users with HBV-related cirrhosis.

Hepatitis B and C Infection May Increase Risk for Parkinson Disease

Hepatitis B and C Infection May Increase Risk for Parkinson Disease

By

While prior studies have found an association between hepatitis C and the risk for Parkinson disease, the association between hepatitis B and Parkinson disease is new and needs further confirmation.

HBV, HCV Could Be Wiped Out as Public Health Threats by 2030

HBV, HCV Could Be Wiped Out as Public Health Threats by 2030

Despite being the seventh leading cause of death in the world, viral hepatitis accounts for less than 1% of the National Institutes of Health research budget.

Pharmacist Interventions Can Help to Optimize HCV Treatment

Pharmacist Interventions Can Help to Optimize HCV Treatment

By

Clinical pharmacists can encourage preventive measures on reducing HCV transmission, increase education adherence, assist in initiating HCV treatment, assist in monitoring clinical and adverse effects, and facilitate medication acquisition.

FDA Approves First HCV Drugs for Children and Adolescents

FDA Approves First HCV Drugs for Children and Adolescents

By

Harvoni (ledipasvir and sofosbuvir) has been approved for children with HCV genotype 1, 4, 5, or 6 infection. Sovaldi (sofosbuvir) has been approved for children with HCV genotype 2 or 3 infection, in combination with ribavirin.

HCV Infection May Increase Risk for Cataract Formation

HCV Infection May Increase Risk for Cataract Formation

By

HCV infection is associated with an increased risk for cataract formation, possibly due to HCV-related oxidative stress. Some treatment regimens, such as interferon/ribavirin combination therapy, also increase the risk for cataracts.

Rate of HBV Reactivation in Chronic Hepatitis C Patients Receiving DAAs

Rate of HBV Reactivation in Chronic Hepatitis C Patients Receiving DAAs

Hepatitis B virus reactivation may occur in patients with chronic hepatitis C with current HBV infection treated with direct-acting antivirals.

Multiple DAA Regimens Safe, Efficacious for Treating HCV Genotype 1

Multiple DAA Regimens Safe, Efficacious for Treating HCV Genotype 1

Several direct-acting antiviral regimens were shown to be safe, tolerable, and efficient in treating hepatitis C virus genotype 1 infection.

Clinical Guideline on Evaluating Abnormal Liver Chemistries

Clinical Guideline on Evaluating Abnormal Liver Chemistries

By

The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.

FDA Expands Indication, Adds Boxed Warning for HCV Drug

FDA Expands Indication, Adds Boxed Warning for HCV Drug

By

FDA expanded indication for Technivie (ombitasvir, paritaprevir, ritonavir; AbbVie) and added a boxed warning for treatment of patients with HCV infection with compensated cirrhosis.

Low Rates of HCV Testing Seen in Baby Boomers

Low Rates of HCV Testing Seen in Baby Boomers

Of 76.2 million baby boomers in the US in 2015, only 10.5 million had been tested for hepatitis C, according to new research.

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

By

The incidence of hepatocellular carcinoma after sustained virological response has not increased with the widespread use of all oral direct antivirals regimens as suggested in previous studies, according to a new study.

French Study Points to Eradication of HIV-HCV Coinfection

French Study Points to Eradication of HIV-HCV Coinfection

By

Prevalence of active HIV-HCV coinfection may decrease to 1.1% in France over the next decade.

Antivirals Effective in Patients With HCV Infection and Hemophilia

Antivirals Effective in Patients With HCV Infection and Hemophilia

By

A phase 2b trial showed that direct-acting antivirals were effective for treating hepatitis C virus infection in patients with inherited bleeding disorders.

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

By

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

HCV Infection Linked to Nonhepatic Cancers in the Elderly

HCV Infection Linked to Nonhepatic Cancers in the Elderly

By

In the elderly population, hepatitis C virus infection is associated with cancers other than hepatocellular carcinoma, such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

By

Neuropsychiatric syndrome not linked to virus in hepatitis C infection.

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

By

Customized CBT reduced substance use disorder, pain severity, and pain interference in veterans with HCV.

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

By

Priority Review granted to the NDA of glecaprevir/pibrentasvir (G/P; AbbVie) for the treatment of genotypes 1-6 chronic hepatitis C virus infection.

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

By

Using telemedicine consults with specialists to support PCPs enhanced the treatment rates in hepatitis C in rural areas.

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Sustained viral response correlated with a significant decrease in the risk of diabetes mellitus and a trend towards decrease in chronic renal failure, according to a study.

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

By

Trial finds the combination of simeprevir, daclatasvir, and sofosbuvir generally safe and well tolerated in HCV patients with decompensated liver disease.

Sign Up for Free e-newsletters